Cost-Per-Responder Analysis of Delgocitinib Topical Cream Versus Dupilumab Subcutaneous Injection for Moderate to Severe Atopic Hand Eczema in the United States
Main Article Content
Keywords
delgocitinib, atopic hand eczema, dupilumab
References
2. Quaade AS et al. 2021. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis;
3. Weisshaar E. 2024. Chronic Hand Eczema. Am J Clin Dermatol;
4. Cazzaniga et al. 2016. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. J Eur Acad Dermatol Venereol;
5. Van Gils RF et al. 2009. Integrated, multidisciplinary care for hand eczema: design of a randomized controlled trial and cost-effectiveness study. BMC Public Health;
6. FDA. 2025. Prescribing information: Anzupgo (delgocitinib);
7. Bissonnette et al. 2024. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet;
8. FDA. 2022. Prescribing information: Dupixent (dupilumab);
9. LEO Pharma. 2024. MAIC of delgocitinib (DELTA 1 & 2) vs. dupilumab (LIBERTY-AD-HAFT) (only in AD subtype of CHE) [data on file];
10. Cohen et al. 2024 Matching-adjusted indirect comparison of the efficacy of delgocitinib and dupilumab in the treatment of moderate to severe atopic hand eczema. EADV 2024. Oral presentation;
11. Sanders et al. 2016. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA;
12. Borg et al. 2024. The management of Chronic Hand Eczema: A retrospective patient record review. Contact Dermatitis;
13. LEO Pharma. 2024. Clinical trial report: Openlabel Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA 3) [data on file];
14. NAVLIN by EVERSANA. 2025. Pricing database, Anzupgo, WAC;
15. NAVLIN by EVERSANA. 2025. Pricing database, Dupixent, WAC;
16. Centers for Medicare and Medicaid Services. 2024. Physician Fee Sched
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.